<DOC>
	<DOCNO>NCT02655159</DOCNO>
	<brief_summary>This national , multicenter , retrospective , observational post-authorization study ( EPA-OD ) study . The study conduct review medical record patient start study . In case , data start study obtain order ensure retrospective nature , thus reflect regular use nab-paclitaxel clinical practice avoid interference physician 's clinical practice . To ensure observational nature study , data collect whenever available patient 's medical record , diagnostic therapeutic intervention outside regular clinical practice use .</brief_summary>
	<brief_title>Study Nab-paclitaxel ( Abraxane® ) Treatment Patients With Metastatic Breast Cancer Routine Clinical Practice</brief_title>
	<detailed_description>This national , multicenter , retrospective , observational post-authorization study ( EPA-OD ) study . Investigators include consecutive adult patient diagnose HER2-negative MBC start treatment nab-paclitaxel monotherapy third line chemotherapy metastatic disease past 3 year ( 2012-2014 ) . These patient must meet inclusion criterion none exclusion criterion establish protocol . The primary objective describe effectiveness nab-paclitaxel term response early line chemotherapy metastatic breast cancer routine clinical practice . This study plan collect data retrospectively , provide available patient 's medical record accord routine clinical practice .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Women ≥18 year age . Confirmed diagnosis MBC ( stage IV ) . Breast adenocarcinoma confirm histologically . HER2negative accord American Society Clinical Oncology ( ASCO ) Anatomical Pathology ( CAP ) criterion detection HER2 breast cancer . Patients start treatment nabpaclitaxel monotherapy third line chemotherapy metastatic disease HER2negative breast cancer period 20122014 ( 3 year ) receive least one cycle treatment . Ability give inform consent , preferably write orally front witness , start data collection ( able give ) . Patients medical psychological disorder investigator 's opinion might compromise ability patient give inform consent . Patients receive treatment nabpaclitaxel combine chemotherapy agent antiangiogenic drug tumortargeting drug antitumor activity . Patients take part clinical trial ( interventional ) study period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Observational</keyword>
	<keyword>Retrospective</keyword>
	<keyword>AMBER</keyword>
</DOC>